• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Ask AI
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.de
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Press

VASRO GmbH > Press
VASRO GmbH

ESG-driven Stock Report: Integration of Sustainability Assessments into Pharma Portfolios

  • July 18, 2025
  • Pharma & Biotech
ESG-gesteuerter Aktienbericht: Wie Nachhaltigkeitsbewertungen gezielt in Pharma-Portfolios integriert werden und Investoren davon profitieren.
Continue Reading
VASRO GmbH

Pharma Disruptors: Stock Valuation Rankings of the Next Generation of Drug Developers

  • July 17, 2025
  • Pharma & Biotech
Pharma-Disruptoren im Fokus: Welche Kennzahlen und Rankings sind für die Bewertung innovativer Arzneimittelentwickler und deren Aktien entscheidend?
Continue Reading
VASRO GmbH

Biotech Stock Valuation Models: Advanced Forecasting Techniques Explained

  • July 16, 2025
  • Pharma & Biotech
Biotech-Aktienbewertungsmodelle nutzen fortschrittliche Prognosetechniken, um Unsicherheiten, Risiken und Chancen im Biotech-Sektor präzise zu bewerten.
Continue Reading
VASRO GmbH

Convergence of Health Technology: Insights from the Equity Report on Digital Health Startups

  • July 15, 2025
  • Pharma & Biotech
Konvergenz der Gesundheitstechnologie: Wie digitale Gesundheits-Startups durch Innovation, Investitionen und neue Geschäftsmodelle laut Equity Report wachsen.
Continue Reading
VASRO GmbH

Top Equity Report Tools: Software and Data Platforms for Investors in 2025

  • July 14, 2025
  • Tech
Top-Aktienbericht-Tools 2025: Die besten Software-Lösungen und Datenplattformen für Investoren mit Fokus auf Analyse, Datenqualität und Sicherheit.
Continue Reading
VASRO GmbH

Why ESG Metrics Matter: Analyzing Equity Reports in Biotech and Pharma

  • July 11, 2025
  • Pharma & Biotech
ESG-Kennzahlen wichtig: Sie fördern nachhaltige Investments, stärken Risikomanagement und sichern langfristigen Erfolg in Biotech und Pharma.
Continue Reading
VASRO GmbH

Global Energy Equity Trends and Market Intelligence for a Renewable Future

  • July 10, 2025
  • Energy
Global Energy Equity trends and market intelligence reveal how renewables drive fair access, investment, and innovation for a sustainable energy future.
Continue Reading
VASRO GmbH

Small-Cap Tech Stocks equity report techniques to spot hidden value

  • July 9, 2025
  • Tech
Spot hidden value in small-cap tech stocks with proven equity report techniques, focusing on key metrics, qualitative analysis, and risk management.
Continue Reading
VASRO GmbH

Pharma Equity Outlook: 2025 Growth Projections and Key Market Drivers

  • July 8, 2025
  • Pharma & Biotech
Pharma Equity Outlook for 2025 highlights growth projections, key market drivers, and the impact of innovation, R&D, and digital transformation.
Continue Reading
VASRO GmbH

AI in Equity Forecasting and its impact on 2025 market intelligence

  • July 7, 2025
  • Unkategorisiert
AI in equity forecasting boosts accuracy, speed, and insight, transforming 2025 market intelligence and empowering financial professionals with real-time data.
Continue Reading

Posts pagination

Previous 1 … 15 16 17 … 37 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705 October 12, 2026
Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform September 29, 2026
Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion September 16, 2026
Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • info@vasro.de
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.